ASNS

Across TCGA pan-cancer cohorts, ASNS mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ASNS’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ASNS mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ASNS is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where ASNS tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ASNS mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.865	<.001	12	view →
HNSC	Male	IV	+0.818	<.001	11	view →
LSCC	Male	III,IV	+1.339	<.001	9	view →
LUAD	Male	III,IV	+1.137	<.001	9	view →
COAD	Male	II,III,IV	+0.744	<.001	9	view →
PDAC	Female	II,III,IV	−1.603	<.001	7	view →
OV	All	All	+0.745	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ASNS–CCRCC

Open the CCRCC breakdown →